Canaccord lowered the firm’s price target on Cresco Labs (CRLBF) to C$2.25 from C$2.50 and keeps a Speculative Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRLBF:
- Cresco Labs Grows Cash Flow and Margins Despite 2025 Impairment Charges
- Is CRLBF a Buy, Before Earnings?
- Cresco Labs Sets March 5 Date to Report Q4 and Full-Year 2025 Results
- Cresco Labs Launches US$100 Million At-the-Market Equity Program
- Cresco Labs Expands Florida Footprint With New Sunnyside Tamarac Dispensary